XBIT (XBiotech) ROCE %: -15.65% (As of Mar. 2026)


XBIT XBiotech Inc XBIT
32 GF Score
Price $2.34
! 2 Warning Signs
View Full Analysis

What is XBiotech ROCE %?

XBiotech XBIT +0.65% 32 ROCE % is -15.65% as of Mar. 2026. GuruFocus rates XBIT with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. XBiotech's annualized ROCE % for the quarter that ended in Mar. 2026 was -15.65%.

XBiotech  (NAS:XBIT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

XBiotech ROCE % Related Terms

XBiotech ROCE % Historical Data

* Premium members only.

The historical data trend for XBiotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XBiotech ROCE % Chart

XBiotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.07 -13.43 -10.51 -18.67 -27.73

XBiotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.90 -3.94 -13.75 -68.98 -15.65
XBIT
32GF Score
XBiotech Inc XBIT
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XBiotech ROCE % Calculation

XBiotech's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-45.217/( ( (199.093 - 15.105) + (150.082 - 7.929) )/ 2 )
=-45.217/( (183.988+142.153)/ 2 )
=-45.217/163.0705
=-27.73 %

XBiotech's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-21.824/( ( (150.082 - 7.929) + (139.836 - 2.999) )/ 2 )
=-21.824/( ( 142.153 + 136.837 )/ 2 )
=-21.824/139.495
=-15.65 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -15.65% mean?
XBiotech (XBIT) has a ROCE % of -15.65% as of Mar. 2026.
Is XBiotech's ROCE % too high?
XBiotech's current ROCE % is -15.65%. Overall, XBiotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does XBiotech's ROCE % compare to FLNA and MCRB?
XBiotech's ROCE % of -15.65% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. XBiotech's current ROCE % is -15.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XBiotech stock overvalued right now?
XBiotech (XBIT) has a current ROCE % of -15.65%. The current ROCE % is -15.65%. XBiotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For XBiotech (XBIT), the current ROCE % is -15.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XBiotech Business Description

Other Exchanges 4XB:Germany
Address 5217 Winnebago Lane, Austin, TX, USA, 78744
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
32GF Score

Get the complete analysis for XBIT

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.34
Price